Trade Summary

2 days ago, Burrows Scott L, serving as CFO at Spyre Therapeutics, Inc. (SYRE), sold 2,500 shares at $40.65 per share, for a total transaction value of $101,620.00. Following this transaction, Burrows Scott L now holds 97,994 shares of SYRE.

This sale represents a 2.00% decrease in Burrows Scott L's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 3, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 3, 2026, meaning the disclosure happened on the same day as the trade.

Spyre Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.